Skip to main content
Premium Trial:

Request an Annual Quote

CuraGen Posts Widened Loss in Q4; Paints Grim Outlook for 02

NEW YORK, Jan. 31 - CuraGen on Thursday reported that swelling research and development expenses managed to double its net loss in the fourth quarter, and the 2002 revenues would only reach 75 percent of 2001 revenues.

Loss in the period ended on Dec. 31 widened to $16.2 million, or 33 cents per share, compared with $8.6 million, or 21 cents per share, one year ago.

Revenues rose 5.2 percent to $5.5 million from $5.2 million in the same period last year.

CuraGen also said it expects to initiate 20 protein therapeutic projects in 2002, and said it will submit two applications with the US Food and Drug Administration to begin clinical trials with protein-based drugs.

Operating loss in 2002 will likely be between 60 percent and 70 percent of its 2001 loss, the company said.

Revenue for fiscal 2001 increased 12.7 percent to $23.5 million, compared to $20.8 million for fiscal 2000, CuraGen said. R&D spending increased almost 61 percent to $65.8 million for fiscal 2001, compared to $41 million for fiscal 2000.

 

CuraGen had available cash resources and short-term investments of approximately $508 million, it said.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.